AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Anaconda Biomed secures $56 million financing led by Omega Funds, with support from new and existing investors. The funds will aid product development and clinical studies for its thrombectomy catheters.
Amount Raised
$56 Million
Round Type
Venture - Series Unknown
BarcelonaBiotechnologyHealth CareMedicalMedical DeviceInvestors
Description
Anaconda Biomed has announced the closing of a $56 million financing round to support product development and clinical work related to its novel thrombectomy catheters. This financing round was led by Omega Funds and includes participation from various new and existing investors. The funds will be utilized for the ongoing ATHENA pivotal IDE study, which evaluates the safety and performance of the ANA Funnel Catheter. CEO Trent Reutiman emphasized the significance of this funding in advancing treatments for ischemic stroke.
Fundz sees it the moment Anaconda BioMed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
Based on industry dataAnaconda BioMed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.